Dendreon falls on good ASCO data for rival J&J's Zytiga in pre-chemo prostate cancer
13:20 EDT 5 Jun 2012 | SCRIP
Johnson & Johnson grabbed much attention at the American Society of Clinical Oncology meeting in Chicago with promising data from the Phase III COU-AA-302 study of the targeted anticancer Zytiga (abiraterone) in chemo-naïve men with.....
Original Article:
More From BioPortfolio on "Dendreon falls on good ASCO data for rival J&J's Zytiga in pre-chemo prostate cancer "
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
